Hepatitis D Virus Infection Among Hepatitis B Surface Antigen Carriers and in “Isolated anti-HBc” Antibodies Profile in Central Tunisia

Salma Mhalla, 1,2,* Yosr Kadri, 2 Sana Alibi, 1 Amel Letaief, 3 Jalel Boukadida, 1 and Naila Hannachi 1

1 Laboratory of Microbiology and Immunology, F. Hached Teaching Hospital, (UR12SP34) University of Sousse, Sousse, Tunisia
2 Department of Microbiology, Fattouma Bourguiba Teaching Hospital, University of Monastir, Monastir, Tunisia
3 Department of Infectious Disease, F. Hached Teaching Hospital, University of Sousse, Sousse, Tunisia
*Corresponding Author: Salma Mhalla, Department of Microbiology, Fattouma Bourguiba Teaching Hospital, University of Monastir, Monastir, Tunisia. E-mail: smhalla@gmail.com

1. Background

Hepatitis D is a major global health problem affecting 15 to 20 million individuals worldwide (1, 2). Hepatitis D virus (HDV) is a small defective RNA virus dependent on Hepatitis B virus (HBV) for its replication and expression (3). The global prevalence of HDV is poorly known due to lack of studies in several parts of the world (4, 5). It is estimated that 5-20% of Hepatitis B surface antigen (HBsAg) carriers are co-infected with HDV. HDV infection results in more severe chronic hepatitis B and occasionally fulminant form of acute hepatitis in co-infected patients (6). Dual HDV-HBV infection results in a 2-fold increase in mortality and a more rapid progression to cirrhosis and hepatocellular carcinoma compared with HBV infection without HDV (1, 4, 7).

Several cross-sectional studies showed that HDV infection is frequently associated with suppressed HBV replication, reducing the rate of HBV DNA and with fluctuation of HBsAg production (8, 9). Many Tunisian studies have been conducted to determine epidemiology and risk factors of HBV infection (10-12). HDV infection and its risk factors have been little studied in our country.

2. Objectives

The aim of this study was to estimate the prevalence and main related risk factors of HDV infection in the center of Tunisia in two groups of patients with different HBV serum markers.

3. Patients and Methods

3.1. Population

In this cross-sectional study, 649 patients attending Farhat HACHED hospital for known HBV infection or systematic screening were included. Patients’ sera had reached the laboratory of virology between January 2011 and April 2012. There were two groups of patients; 540 HBsAg positive carriers and 109 “isolated anti-HBc” antibodies carriers with positive anti-HBc antibodies and negative HBsAg and anti-HBs antibodies (Table 1).

Informed consent was obtained from each patient and a questionnaire was filled including the following data: age, gender, history of blood transfusion or scarifications, intravenous drug abuse, “high-risk” sexual behavior and history of familial hepatitis, clinical symptoms and alanine aminotransferase (ALT) elevation level.
3.2. Serological Tests

Serum samples were already tested for markers of hepatitis B (HBsAg, HBeAg, anti-HBs, anti-HBc and anti-HBe antibodies) by automated microparticle enzyme immunoassay (Axsym system / Abbott®, Germany) with sensitivity of 98-100% and specificity of 97-99.5%. Samples were then tested for anti-HDV antibodies (IgG) with third generation enzyme-linked immunosorbent assay (Globe Diagnostics®, Italy) with sensitivity and specificity of 99.8 and 100%.

3.3. Molecular Tests

Detection of HBV DNA by polymerase chain reaction (PCR) was performed in patients with an “isolated anti-HBc” profile and concerned two regions of the HBV genome: the pre-S and C regions with a global sensitivity of $10^3$ copies/mL. After extraction of the DNA (QIAamp DNA Blood Mini kit; Qiagen®), amplification in the pre-S region was performed by a classical PCR according to the protocol of Lindh (13). Then, a nested PCR was performed in the C region according to a protocol described by Alhababi (14).

3.4. Statistical Analysis

Data analysis was performed by software Epi Info version 6.0, using Chi2 and Fisher’s exact tests. A P < 0.05 was considered statistically significant. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

4. Results

Overall, 649 patients were enrolled in this study. The mean age was 36.01 ± 11.6 years (14 to 82 years) and male/female ratio was about 0.7. These patients were active carriers in 95 patients (14.6%). HBeAg had positive result in 34 patients and all of them belonged to the first group (Table 2). Among these positive HBeAg, there were 17 cases of chronic hepatitis B, including 14 active hepatitis and 17 cases discovered during a routine screening. In the “isolated anti-HBc” profile group, the average age was 31.3 ± 9.6 years, gender ratio was 0.6 and 17.4% of patients had at least one clinical symptom or biological disorders (Table 2).

Of 649 patients, 49 had positive result for HDV IgG antibodies, yielding an overall seroprevalence of 7.5%. There was no significant difference between HDV-positive and HDV-negative patients regarding sex (male/female ratio = 0.7) and mean age (32.2 years vs. 35 years, P > 0.05). HBeAg was absent in 84% of HDV positive sera.

In the first group, the prevalence of positive HDV antibodies was 8% (44/540 patients). No significant association was observed between hepatitis D and family history of jaundice or personal history of blood transfusion or having multiple sex partners (Table 3). However, there was a significant higher rate of HDV negative status in HBsAg asymptomatic (inactive) carriers ($P < 10^{-3}$, OR = 9, 95% CI: [4.48-18.58]). Among patients with active hepatitis and positive HDV status, most frequent symptoms were jaundice and elevated ALT ($P < 10^{-3}$) (Table 3).

In the second group, 5/109 patients had positive HDV antibodies (4.6%). These five patients had positive anti-HBe antibodies and all of them were asymptomatic; two candidates for medically assisted reproduction, two blood donors and one pregnant women. In this group, HBV DNA was detected in 4/109 sera (3.6%), but in none of the five HDV positive ones.

Table 1. General Characteristics of Studied Population

| Variables                             | Group 1 Positive HBsAg | Group 2 “Isolated Anti-HBc” Profile | Total    |
|---------------------------------------|------------------------|------------------------------------|----------|
| Known chronic HBsAg carriers          | 335 (62)               | 0                                  | 335 (51.6) |
| Systematic screened patients for HBsAg|                        |                                    |          |
| Pregnant women                        | 100 (18.5)             | 35 (32.1)                          | 135 (21) |
| Candidates for medically assisted reproduction | 64 (11.9)               | 44 (40.4)                          | 108 (16.6) |
| Poly transfused                       | 22 (4.1)               | 5 (4.6)                            | 27 (4.1) |
| Health care workers                   | 10 (1.8)               | 8 (7.3)                            | 18 (2.7) |
| Blood donors                          | 9 (1.7)                | 17 (15.6)                          | 26 (4)   |
| Total                                 | 540 (100)              | 109 (100)                          | 649 (100) |

aValues are expressed as No. (%).
### Table 2. Different Symptoms/Biological Disorders in the Two Studied Groups^a^  

| Variables                        | Group 1 HBsAg Positive (n = 540) | Group 2 “Isolated Anti-HBc” Profile (n = 109) | Total      |
|----------------------------------|----------------------------------|---------------------------------------------|------------|
| Asymptomatic patients            | 464 (86)                         | 90 (82.5)                                    | 554 (85.4) |
| Symptomatic patients b           | 76 (14)                          | 19 (17.4)                                    | 95 (14.6)  |
| Symptoms/biological disorders    |                                  |                                             |            |
| Jaundice                         | 22 (4)                           | 3 (2.7)                                      | 25 (3.8)   |
| Elevated ALT > 40, UI/L c        | 55 (10)                          | 12 (11)                                      | 67 (10.3)  |
| Cirrhosis                        | 8 (1.4)                          | 4 (3.6)                                      | 12 (1.8)   |
| Liver function failure           | 4 (0.7)                          | 0                                            | 4 (0.6)    |
| Positive HBeAg                   | 34 (6.3)                         | 0                                            | 34 (5.2)   |

^a^Values are expressed as No. (%).

^b^One patient may have more than one symptom or biological disorders.

^c^Alanine Aminotransferase.

### Table 3. Distribution of Positive HDV Antibodies According to Risk Factors and Clinical/Biological Condition Among 540 HBsAg Carriers

| Variables                        | Prevalence of HDV Ab | Total | P Value | OR | CI 95% |
|----------------------------------|----------------------|-------|---------|----|--------|
|                                  | Positive (n = 44)    | Negative (n = 496) |         |    |        |
| Risk factors^a^                  |                      |                   |         |    |        |
| History of hepatitis B in the family | 1 (3.5)              | 27 (5.4)          | 28      | 0.7| 0.4    | 0.01-2.58 |
| Surgery                          | 0                    | 20 (4)            | 20      | 0.3| NA     | NA       |
| Transfusions                     | 0                    | 24 (4.8)          | 24      | 0.2| NA     | NA       |
| Tattoo/scarifications            | 3 (12.5)             | 21 (4.2)          | 24      | 0.4| 1.6    | 0.3-5.9  |
| Multiple sex partners            | 0                    | 7 (1.4)           | 7       | > 0.99| NA     | NA       |
| Intravenous drug users           | 0                    | 2 (0.4)           | 2       | > 0.99| NA     | NA       |
| Clinical/biological condition    |                      |                   |         |    |        |
| Asymptomatic carriage of HBsAg   | 21 (4.5)             | 443 (89.3)        | 464     | <10^-3 | 9      | 4.48-18.58 |
| Symptomatic patients b           | 23 (30.2)            | 53 (10.7)         | 76      |       |       |          |
| NA Jaundice                      | 6 (27.2)             | 16 (0.3)          | 22      | <10^-3 | 4.7   | 1.42-13.63 |
| NA Cirrhosis                     | 1 (12.5)             | 7 (1.4)           | 8       | 0.49  | 1.6    | 0.03-13.11 |
| NA liver function failure        | 1 (25)               | 3 (0.6)           | 4       | 0.28  | 3.8    | 0.07-48.5 |
| NA Elevated ALT > 40, UI/L       | 10 (18.1)            | 45 (9)            | 55      | <10^-3 | 2.9   | 1.21-6.59 |
| Positive HBeAg                   | 4 (11.7)             | 30 (6)            | 34      | 0.5   | 1.5    | 0.37-4.73 |

Abbreviations: Ab, antibodies; ALT, alanine aminotransferase.

^a^One patient may have more than one risk factor.

^b^One patient may have more than one symptom or biological disorders.

### 5. Discussion

Prevalence and risk factors of HDV infection are closely related to those of HBV (15). Tunisia is an intermediate endemicity area for hepatitis B, but HDV prevalence is not well known in some parts of the country (11, 16). In our study, the prevalence of anti-HDV antibodies in inactive HBsAg carriers was 4%. When compared to previous Tunisian studies, our result confirms the declining trend of hepatitis D prevalence from 33% in 1990 (17) and 16.1% in 1997 (11) to 6.8% in 2009 (16). This decrease can be explained by improvements of socioeconomic conditions, awareness of transmitting viruses and above all, a better control of HBV infection and systematic vaccination since 1995. A decline in HDV infection has also been reported since the 90th in others countries with low endemicity of HBV infection such as Italy, Spain, Turkey and Taiwan (18-20). However, in the last decade the prevalence of HDV remained constant in some countries such as England and France, due to migration of subjects from endemic areas (1). In contrast, the prevalence of HDV may exceed 60% in countries of high endemicity for HBV, such as India or center Africa (21, 22).

In our work, none of the studied risk factors was associated with HDV infection; although, the possibility of missing bias cannot be excluded. In Anglo-Saxon countries, the main risk factor for infection with HDV is intravenous...
addiction (23, 24). In endemic areas, household transmission is the most common mode of transmission for HDV, but sexual and nosocomial risk were described (25). This intra-familial contamination is probably important in our country, as it is prominent in HBV transmission (11, 12, 26).

According to Tunisian and European data, our study showed no significant difference in HDV prevalence between the two genders (17, 27). Furthermore, more than 80% of HDV positive patients have negative result for HBeAg. Other studies showed similar results with up to 90% of HDV (+) patients having negative finding for HBeAg (28, 29). These findings may be due to high rate of precore region mutations, which can exceed 90% of Tunisian patients infected chronically with HBV (30-32). In addition, it has been described that HDV inhibits the expression of HBeAg through its ribozymes, which are enzymes able to destroy mRNAs that encode for Pre/C region (33).

Our data showed that patients with jaundice and elevated ALT were more likely to have HDV-positive status than inactive HBsAg carriers, which could be explained by a more severe infection in co-infected patients (HBV/HDV). As proposed in other countries such as the USA, HDV status is searched in all patients with active B hepatitis (30, 34, 35). In our study, there was no correlation between cirrhosis, liver failure and HDV-positive status, but these two pathologies were not enough represented. Indeed, other studies conducted on a larger population of positive HDV patients, have shown rapid and frequent progression to liver cirrhosis and liver failure (34).

In the “isolated anti-HBC” profile group, the prevalence of HDV was about 4.5%, which is almost similar to the level found in inactive HBsAg carrier’s group. Positive HDV status may reflect either past healed co/super-infection or current co/super-infection with both viruses. HBsAg and HBV-DNA apparently fluctuate in longitudinally studied patients because of interaction and competition between HBV and HBV/HDV. As proposed in other countries such as the USA, HDV status is searched in all patients with active B hepatitis (30, 34, 35). In our study, none of the five positive-HDV patients had detectable HBV-DNA. The use of more sensitive technique with lower threshold may allow us not to miss occult hepatitis B associated with HDV, we would propose that future Tunisian guidelines emphasize the relevance to test for HDV in all patients with active B hepatitis. Also not to miss HDV infection among patients with occult hepatitis B, especially in population of high risk of spread of both viruses.

Footnotes

Authors’ Contribution: Study concept and design: Salma Mhalla and Naila Hannachi; acquisition of data: Salma Mhalla and Sana Alibi; analysis and interpretation of data: Salma Mhalla, Naila Hannachi and Yosr Kadri; drafting of the manuscript: Salma Mhalla; critical revision of the manuscript for important intellectual content: Naila Hannachi; statistical analysis: Salma Mhalla and Sana Alibi; administrative, technical and material support: Jalel Boukadida; study supervision: Jalel Boukadida and Alem Letaief.

Funding/Support: This study was funded by the ministry of higher education, scientific research and technology: research unit “genomic characterization of infectious agents UR12SP34”.

References

1. Rizzetto M. Hepatitis D: thirty years after. J Hepatol. 2009;50(5):1043-50. doi: 10.1016/j.jhep.2009.01.004. [PubMed: 19285743]
2. Saravanan S, Velu V, Kumarasamy N, Shankar EM, Nandakumar S, Murugavel KG, et al. Seroprevalence of hepatitis delta virus infection among subjects with underlying hepatic diseases in Chennai, southern India. Trans R Soc Trop Med Hyg. 2008;102(6):793-6. doi: 10.1016/j.trstmh.2008.05.001. [PubMed: 18556053]
3. Rizzetto M, Purcell RH, Gerin JL. Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet. 1980;3(8180):325-8. [PubMed: 6104036]
4. LunelFabianni F, Mansour W, Amar AO, Aye M, Le Gal F, Malick FZ, et al. Impact of hepatitis B and delta virus coinfection on liver disease in Mauritania: a cross sectional study. J Infect. 2013;67(5):448-57. doi: 10.1016/j.jinf.2013.06.008. [PubMed: 23796871]
5. Amini N, Alavian SM, Kabir A, Aalaee-Andabili SH, Saiedi Hosseini SY, Rizzetto M. Prevalence of hepatitis D in the eastern Mediterranean region: systematic review and meta analysis. Hepat Mon. 2013;13(6):e8210. doi: 10.5812/hepatmon.8210. [PubMed: 23554822]
6. Govindarajan S, Chin KP, Redeker AG, Peters RL. Fulminant B viral hepatitis: role of delta agent. Gastroenterology. 1984;86(6):3477-20. [PubMed: 674570]
7. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46(3):420-6. [PubMed: 10671308]
8. Schaper M, Rodríguez-Frias F, Jardi R, Tabernero D, Horns M, Ruiz G, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52(5):658-64. doi: 10.1016/j.jhep.2009.10.036. [PubMed: 20345531]
9. Wedemeyer H. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol. 2005;42(5):627-9. doi: 10.1016/j.jhep.2010.02.001. [PubMed: 20349471]
10. Triki H. [Epidemiology of hepatitis B virus, hepatitis C virus and Delta virus in the general population and in liver cirrhosis in Tunisia]. Arch Inst Pasteur Tunis. 1994;73(3-4):403-6. [PubMed: 8801835]
11. Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg. 1997;91(3):264-7. [PubMed: 9320773]

12. Hannachi N, Bahri O, Mhalla S, Marzouk M, Sadrnoua A, Belguit A, et al. Hepatitis B virus infection in Tunisian pregnant women: risk factors and viral DNA levels in HBc antigen negative women. Pathol Biol (Paris). 2009;57(1):43-7. doi: 10.1016/j.patbio.2008.04.007. [PubMed: 18513893]

13. Lindh M, Andersson AS, Gudsal Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus–large-scale analysis using a new genotyping method. J Infect Dis. 1997;175(6):1285-93. [PubMed: 918065]

14. Alhababi F, Sallam TA, Tong CY. The significance of ‘anti-HBc only’ in the clinical virology laboratory. J Clin Virol. 2003;27(2):162-9. [PubMed: 12829038]

15. Rizzetto M. Hepatitis delta: the virus and the disease. J Hepatol. 1996;18 Suppl 1:S145-6. [PubMed: 9564206]

16. Djebbi A, Rebai WK, Bahri O, Hoggna N, Sadrnoua A, Triki H. [Sero- logical markers, viral RNA and genotype of hepatitis delta virus in HBs antigen positive Tunisian patients]. Pathol Biol (Paris). 2009;57(7):518-23. doi: 10.1016/j.patbio.2008.09.010. [PubMed: 19035909]

17. Jenhani F, Ayed K, Gorgi Y, Zoulim F, Picoud C, Tregio C. Delta infection in chronic HBs Ag carriers in Tunisia: high prevalence in chronic asymptomatic HBs Ag carriers and in HBs Ag positive cirrhosis. Ann Trop Med Parasitol. 1999;93(4):349-53. [PubMed: 22608999]

18. Gaeta GB, Stroffolini T, Chiaramonte M, Ascone T, Stornaiuolo G, Lobello S, et al. Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology. 2000;32(4 Pt 1):824-7. doi: 10.1053/jhep.2000.17711. [PubMed: 11003629]

19. Degertekin H, Yalcin K, Yakut M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey: an analysis of clinical studies. Turk J Gastroenterol. 2006;17(1):25-34. [PubMed: 16830274]

20. Huo TI, Wu JC, Lin RY, Sheng WY, Chang FY, Lee SD. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J Gastroenterol Hepatol. 1997;12(10):747-51. [PubMed: 9410041]

21. Acharya SK, Madan K, Datta Gupta S, Panda SK. Viral hepatitis in India. Natl Med J India. 2006;19(4):203-7. [PubMed: 17010199]

22. Makwu M, Caron M, Souciere S, Malonga-Mouele G, Mahe A, Kanzaun M. Prevalence and genetic diversity of hepatitis B and delta viruses in pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8 originates from and is endemic in central Africa. J Clin Microbiol. 2008;46(2):754-6. doi: 10.1128/JCM.02142-07. [PubMed: 18077653]

23. Mele A, Mariano A, Torri ME, Stroffolini T, Pizziutti R, Gallo G, et al. Acute hepatitis delta virus infection in Italy: incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign. Clin Infect Dis. 2007;44(4):377-24. doi: 10.1086/508543. [PubMed: 17205435]

24. Bialek SR, Bower WA, Mottram K, Purchase D, Nakano T, Nainan O, et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health. 2005;82(3):468-78. doi: 10.1093/urbanhealth/nij094. [PubMed: 16049202]

25. Setrani NK, Abbas Z, Raza S, Yakoob J, Jafirs W. Prevalence of hepatitis D in HBsAg positive patients visiting liver clinics. J Pak Med Assoc. 2009;59(7):434-7. [PubMed: 19579728]

26. Ben-Alaya-Bouaff N, Bahri O, Chlif S, Bettaieb J, Toumi A, Bel Haj HN, et al. Heterogeneity of hepatitis B transmission in Tunisia: risk factors for infection and chronic carriage before the introduction of a universal vaccine program. Vaccine. 2010;28(10):1301-7. doi: 10.1016/j.vaccine.2010.02.201. [PubMed: 20226251]

27. Abe K, Hayakawa E, Sminov AV, Rossina AL, Ding X, Huy TT, et al. Molecular epidemiology of hepatitis B, C, D and E viruses among children in Moscow, Russia. J Clin Virol. 2004;30(5):57-61. doi: 10.1016/j.jcv.2003.08.005. [PubMed: 15072755]

28. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manss MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009;16(2):383-94. doi: 10.1111/j.1365-2893.2009.01144.x. [PubMed: 19564789]

29. Arai B, Yazdani MR, Kalantari H, Yaran M, Nokhodian Z, Javadi AA, et al. Hepatitis D virus infection in Isfahan, central Iran: Prevalence and risk factors among chronic HBV infection cases. Hepat Mon. 2011;11(4):269-72. [PubMed: 22706272]

30. Triki H, Ben Slimane S, Ben Mami N, Sakka T, Ben Ammar A, Del-lagi K. High circulation of hepatitis B virus (HBV) precore mutants in Tunisia, North Africa. Epidemiol Infect. 2000;125(3):369-74. [PubMed: 10557973]

31. Bahri O, Cheikli I, Hajji N, Djebbi A, Maamouri N, Sadrnoua A, et al. Hepatitis B genotypes, precore and core promoter mutants circulating in Tunisia. J Med Virol. 2006;78(3):553-7. doi: 10.1002/jmv.20354. [PubMed: 16494235]

32. Ounissa R, Bahri O, Alaya-Bouaff NB, Chouaieb S, Ben Yahia A, Sadrnoua A, et al. Frequency and clinical significance of core promoter and precore region mutations in Tunisian patients infected chronically with hepatitis B. J Med Virol. 2012;84(1):379-26. doi: 10.1002/jmv.22997074

33. Wang CX, Lu YQ, Qi P, Chen LH, Han X. Efficient inhibition of hepatitis B virus replication by hepatitis delta virus ribozymes delivered by targeted retrovirus. Virol. 2010;761; doi: 10.1186/1743-422X-7-61. [PubMed: 22026251]

34. Kushner T, Serper M, Kaplan DI. Delta hepatitis within the Veterans Affairs medical system in the United States: Prevalence, risk factors, and outcomes. J Hepatol. 2015;63(3):586-92. doi: 10.1016/j.jhep.2015.04.025. [PubMed: 25962883]

35. Celen MR, Ayaz C, Hosoglu S, Geyik MF, Ulug M. Anti-hepatitis delta virus seroprevalence and risk factors in patients with hepatitis B in Southeast Turkey. Saudi Med J. 2006;27(5):617-20. [PubMed: 16680248]

36. Ghamari S, Alavian SM, Rizzetto M, Olivero A, Smedile A, Khedive I, et al. Hepatitis B genotypes, precore and core promoter mutants circulating in Tunisia, North Africa. Epidemiol Infect. 2000;125(3):369-74. [PubMed: 10557973]

37. Chakraborty T, Kasturia V, Thakur N, Chakraborty S, Sachdeva SK. Hepatitis B viral DNA levels and viral kinetik in HBs antigen positive Tunisian patients. Pathol Biol (Paris). 2010;58(10):330-7. doi: 10.1016/j.patbio.2010.02.201. [PubMed: 20266251]